Biodexa Pharmaceuticals Plc ADR (BDRX)

$1.71 -0.06 (-3.39%)
Market Cap 4.25M
Revenue (ttm) 0.00
Net Income (ttm) -8.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 3,524,200
Avg Vol 107,716
Day's Range N/A - N/A
Shares Out 2.00M
Stochastic %K 2%
Beta 1.20
Analysts Strong Buy
Price Target $10.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
The_Gambl3r
The_Gambl3r Jul. 22 at 9:34 PM
$BDRX You’re Toast.
1 · Reply
The_Gambl3r
The_Gambl3r Jul. 22 at 9:19 PM
$BDRX 1.75 is all yours dear.
0 · Reply
Reacting_
Reacting_ Jul. 22 at 6:26 PM
$BDRX Another spike in the tank left?
0 · Reply
fun_guy
fun_guy Jul. 22 at 3:59 PM
$BDRX 1.68/1.73
1 · Reply
Currencywolf
Currencywolf Jul. 22 at 2:34 PM
Been banking off @TopSarge alerts these past few weeks. The entries have been insane! Don’t sleep, go give him a follow 🔥 $CLBK $UMAC $BDRX $NNE future runners
0 · Reply
Longintactandinminent
Longintactandinminent Jul. 22 at 1:47 PM
$BDRX heading to san frqncisco
0 · Reply
Zackpedia
Zackpedia Jul. 22 at 1:19 PM
$BDRX Down to 1.7 now, you could’ve sold when I alerted
1 · Reply
luckyluke17
luckyluke17 Jul. 22 at 1:16 PM
$BDRX nothing left
0 · Reply
Trader1141
Trader1141 Jul. 22 at 11:57 AM
$AEHL $BDRX $CHAI $INLF $INM Lmmfao….. bulls got screwed today so far 😆
1 · Reply
luckyluke17
luckyluke17 Jul. 22 at 11:48 AM
$BDRX big short at a high rate this morning. 350K ADR via prefunded warrants probably flooded the market. The rest of that 2.56M ADR registration are warrants that need approval and exercised at 2.85. about 200K ADR via series M could see that 2.85 lower. Shareholders already said no once, we will see.
0 · Reply
Latest News on BDRX
Biodexa Pharmaceuticals Registration statement: Registration filing

Jul 15, 2026, 8:00 AM EDT - 7 days ago

Biodexa Pharmaceuticals Registration statement: Registration filing

Result of Annual General Meeting

Jun 30, 2026, 4:30 PM EDT - 22 days ago

Result of Annual General Meeting

Biodexa Pharmaceuticals announces pricing of $3.5M registered offering

2026-06-30T12:21:15.000Z - 22 days ago

Biodexa Pharmaceuticals announces pricing of $3.5M registered offering

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

Jun 30, 2026, 8:00 AM EDT - 22 days ago

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

Biodexa Pharmaceuticals receives Health Canada approval for Serenta trial

2026-06-29T13:15:56.000Z - 23 days ago

Biodexa Pharmaceuticals receives Health Canada approval for Serenta trial

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Jun 29, 2026, 8:30 AM EDT - 23 days ago

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Postponement and Re-scheduling of Annual General Meeting

Jun 17, 2026, 4:30 PM EDT - 5 weeks ago

Postponement and Re-scheduling of Annual General Meeting

Biodexa issues letter to Shareholders

May 14, 2026, 8:30 AM EDT - 2 months ago

Biodexa issues letter to Shareholders

Biodexa Pharmaceuticals PLC-ADR trading halted, news pending

2026-04-02T23:50:17.000Z - 3 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, news pending

Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene

2026-04-02T13:12:12.000Z - 3 months ago

Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Apr 2, 2026, 8:30 AM EDT - 3 months ago

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Biodexa, Tanner Pharma launch global early access program for FAP patients

2026-03-31T12:47:27.000Z - 4 months ago

Biodexa, Tanner Pharma launch global early access program for FAP patients

Preliminary Results for the Year Ended 31 December 2025

Mar 27, 2026, 5:00 PM EDT - 4 months ago

Preliminary Results for the Year Ended 31 December 2025

Biodexa Pharmaceuticals management to meet with Maxim

2026-03-23T14:45:08.000Z - 4 months ago

Biodexa Pharmaceuticals management to meet with Maxim

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

Mar 23, 2026, 8:30 AM EDT - 4 months ago

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

Biodexa Pharmaceuticals announces one-for-five reverse ADR split

2026-03-18T21:10:28.000Z - 4 months ago

Biodexa Pharmaceuticals announces one-for-five reverse ADR split

ADR Ratio Change

Mar 18, 2026, 5:00 PM EDT - 4 months ago

ADR Ratio Change

Biodexa Pharmaceuticals supports Life’s a Polyp Foundation

2026-03-09T12:40:09.000Z - 4 months ago

Biodexa Pharmaceuticals supports Life’s a Polyp Foundation

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Mar 9, 2026, 8:30 AM EDT - 4 months ago

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Feb 19, 2026, 7:30 AM EST - 5 months ago

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical

2026-02-04T13:36:46.000Z - 6 months ago

Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Feb 4, 2026, 8:30 AM EST - 6 months ago

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary

2026-01-05T13:41:08.000Z - 7 months ago

Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Jan 5, 2026, 8:30 AM EST - 7 months ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering

2025-12-18T13:35:26.000Z - 7 months ago

Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering

Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 7 months ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Pharmaceuticals PLC-ADR trading resumes

2025-12-08T14:41:04.000Z - 8 months ago

Biodexa Pharmaceuticals PLC-ADR trading resumes

Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause

2025-12-08T14:35:30.000Z - 8 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause

Biodexa announces enrollment of first European patients in Phase 3 Serenta trial

2025-12-01T13:35:58.000Z - 8 months ago

Biodexa announces enrollment of first European patients in Phase 3 Serenta trial

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 8 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial

2025-11-24T13:45:58.000Z - 8 months ago

Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 8 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Pharmaceuticals files to sell 3.38M units

2025-11-17T22:05:23.000Z - 8 months ago

Biodexa Pharmaceuticals files to sell 3.38M units

Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP

2025-11-03T13:35:20.000Z - 9 months ago

Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 9 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 10 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Biodexa Pharmaceuticals files $100M mixed securities shelf

2025-09-26T21:05:13.000Z - 10 months ago

Biodexa Pharmaceuticals files $100M mixed securities shelf

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 11 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 11 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 1 year ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 1 year ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 1 year ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 1 year ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 1 year ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 1 year ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 1 year ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 1 year ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

The_Gambl3r
The_Gambl3r Jul. 22 at 9:34 PM
$BDRX You’re Toast.
1 · Reply
The_Gambl3r
The_Gambl3r Jul. 22 at 9:19 PM
$BDRX 1.75 is all yours dear.
0 · Reply
Reacting_
Reacting_ Jul. 22 at 6:26 PM
$BDRX Another spike in the tank left?
0 · Reply
fun_guy
fun_guy Jul. 22 at 3:59 PM
$BDRX 1.68/1.73
1 · Reply
Currencywolf
Currencywolf Jul. 22 at 2:34 PM
Been banking off @TopSarge alerts these past few weeks. The entries have been insane! Don’t sleep, go give him a follow 🔥 $CLBK $UMAC $BDRX $NNE future runners
0 · Reply
Longintactandinminent
Longintactandinminent Jul. 22 at 1:47 PM
$BDRX heading to san frqncisco
0 · Reply
Zackpedia
Zackpedia Jul. 22 at 1:19 PM
$BDRX Down to 1.7 now, you could’ve sold when I alerted
1 · Reply
luckyluke17
luckyluke17 Jul. 22 at 1:16 PM
$BDRX nothing left
0 · Reply
Trader1141
Trader1141 Jul. 22 at 11:57 AM
$AEHL $BDRX $CHAI $INLF $INM Lmmfao….. bulls got screwed today so far 😆
1 · Reply
luckyluke17
luckyluke17 Jul. 22 at 11:48 AM
$BDRX big short at a high rate this morning. 350K ADR via prefunded warrants probably flooded the market. The rest of that 2.56M ADR registration are warrants that need approval and exercised at 2.85. about 200K ADR via series M could see that 2.85 lower. Shareholders already said no once, we will see.
0 · Reply
Trader1141
Trader1141 Jul. 22 at 11:21 AM
$INM $BDRX $AEHL $CHAI $INLF 🤣🤣
0 · Reply
Zackpedia
Zackpedia Jul. 22 at 11:00 AM
$BDRX You should’ve sold at 2.4 earlier
0 · Reply
Paraboljoker
Paraboljoker Jul. 22 at 10:54 AM
$BDRX expected⚠️pd
0 · Reply
Reverselonglol
Reverselonglol Jul. 22 at 10:49 AM
$BDRX so sorry to the bull slonging this. 3 dollars back down to 2.3 in a second.
0 · Reply
Zeestallion
Zeestallion Jul. 22 at 10:44 AM
$VIVS The company expects 500% in revenue growth in 2027! Once we get an update on the offering closing. I'm anticipating a climb back towards those .60s, .70s, .80s, and eventually the .90s. They've partnered up with a TRILLION dollar company Eil Lilly. $ZCMD $SXTC $INLF $BDRX
1 · Reply
phd101
phd101 Jul. 22 at 10:42 AM
$BDRX can run huge
0 · Reply
Longintactandinminent
Longintactandinminent Jul. 22 at 3:09 AM
$BDRX lmao the grid player, the nice guy
0 · Reply
luckyluke17
luckyluke17 Jul. 21 at 9:06 PM
$BDRX buying at these levels ah
0 · Reply
fun_guy
fun_guy Jul. 21 at 8:53 PM
$BDRX 🥺
1 · Reply
Mackie2020
Mackie2020 Jul. 21 at 8:40 PM
$BDRX 😏
1 · Reply
Longintactandinminent
Longintactandinminent Jul. 20 at 5:31 PM
$BDRX intact 🤣🤣🤣🤣🤣🤣
0 · Reply
The_Gambl3r
The_Gambl3r Jul. 20 at 5:25 PM
$BDRX Betting on you!
0 · Reply